Cardiovascular and Renal Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Systematic Review, Meta-analysis, and Meta-regression is a research paper published in Diabetes Care (2023). On theSindex it has a DataRank of 0. It has been cited 44 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Heart, Lung, and Blood Institute
Grant: R01HL153456
National Institutes of Health
Grant: 1R01HL153456-01A1
Clinical and economic value of novel diabetes medications for prevention of cardiovascular disease in type 2 diabetes
FWCI
3.24
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals